Cell Membrane Biophysics as a Therapeutic Interface for Nanomedicine: From Disease-Associated Remodeling to Translational Qualification
Open Access
Abstract
Nanomedicine has yielded clinically useful platforms, including liposomes, albumin-bound nanoparticles, and lipid nanoparticles; yet, many systems translate poorly because of nonspecific biodistribution, limited target-site accumulation, inefficient cellular uptake and intracellular delivery, immune clearance, and off-target toxicity. These bottlenecks are often shaped at cell membrane interfaces, where therapeutic materials are recognized, retained, internalized, or cleared and may elicit unsafe responses. Here, we frame cell membrane biophysics as a therapeutic interface for nanomedicine. We examine how lipid organization and fluidity, mechanics, electrochemical state, glycocalyx architecture, and membrane protein identity shape recognition, adhesion, endocytosis, fusion, trafficking, immune responses, and drug release. We assess how disease-associated membrane remodeling can create candidate therapeutic entry points and delivery barriers across cancer, neurodegeneration, inflammation, infection, and vascular disease. We then analyze receptor-mediated targeting, lipid-domain-associated uptake, membrane-coated nanocarriers, engineered extracellular vesicles, and hybrid platforms, with explicit context-of-use definitions and design boundaries. Finally, we propose translational qualification through function-linked critical quality attributes, mechanism-relevant potency assays, context-matched models, in vivo pharmacology and immune safety, scalable manufacturing, and regulatory evaluation. Progress will depend less on descriptive membrane mimicry than on measurable, reproducible, and qualified membrane-dependent functions.Keywords
This publication has 245 references indexed in Scilit:
- Mimic, target, and adapt: Cell membrane‐coated nanoplatforms for precision and immune‐guided cancer treatmentBMEMat, 2026
- Illuminating the Unseen and Targeting the Untreatable: Aggregation‐Induced Emission Nanoparticles as Intelligent, Immune‐Compatible Tools for Precision Cancer TheranosticsAggregate, 2025
- Engineering Hybrid Extracellular Vesicles for Functional mRNA DeliveryAdvanced Functional Materials, 2025
- Evaluating Red Blood Cells' Membrane Fluidity in Diabetes: Insights, Mechanisms, and Future AspectsDiabetes/Metabolism Research and Reviews, 2024
- Nanotechnology and Cancer Bioelectricity: Bridging the Gap Between Biology and Translational MedicineAdvanced Science, 2023
- Study on the Role of an Erythrocyte Membrane‐Coated Nanotheranostic System in Targeted Immune Regulation of Alzheimer's DiseaseAdvanced Science, 2023
- Tumor Therapy Strategies Based on Microenvironment‐Specific Responsive NanomaterialsAdvanced Healthcare Materials, 2023
- Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate CancerJAMA Oncology, 2018
- Exosome–Liposome Hybrid Nanoparticles Deliver CRISPR/Cas9 System in MSCsAdvanced Science, 2018
- Erythrocyte–Platelet Hybrid Membrane Coating for Enhanced Nanoparticle FunctionalizationAdvanced Materials, 2017